At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Metabolic): A Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Empagliflozin 10 MG and Placebo for Obesity and Heart Failure. Completed, enrolled 165 participants across 2 sites.
Detailed Summary
The aim of this trial is to assess the effect of Empagliflozin on lipid and glucose metabolism as well as volume homeostasis and renal function in elderly and obese patients with increased risk of developing heart failure. No history of established heart failure or diabetes is allowed. The primary hypotheses are that 6 months treatment with Empagliflozin 10 mg a day will: 1) decrease epicardial adipose tissue volume, and 2) reduce estimated extracellular volume compared with placebo.
Study Details
Timeline
Interventions
Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
Placebo matches the active drug in appearance, odor and labelling.